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Abstract In every newborn with even mild hyperphenyla-
laninemia (HPA) tetrahydrobiopterin (BH4) deficiencies
need to be excluded as soon as possible. Differential
diagnosis is most commonly performed by analysis of
urinary neopterin and biopterin. In 2005 a new method for
the measurement of neopterin, biopterin and other pterins in
dried blood spot (DBS) on filter paper was introduced. In
order to evaluate the usefulness of this method as a standard
tool for differential diagnosis of HPAs we analyzed
neopterin, biopterin, pterin and dihydropteridine reduc-
tase activity in DBS from 362 patients with HPA over
the period of five years. Age-dependent reference values
were established for the HPA population. Sixty-four
patients with BH4 deficiency (27 patients with 6-
pyruvoyl-tetrahydropterin synthase deficiency, seven with
GTP cyclohydrolase I deficiency, and 30 with dihydrop-
teridine reductase) were identified. Reference values for
neopterin and biopterin in DBS were calculated for each of
the variants. 6-pyruvoyl-tetrahydropterin synthase and
GTP cyclohydrolase I deficiency can be diagnosed by
neopterin and biopterin analysis alone, while for diagnosis
of dihydropteridine reductase deficiency additional deter-
mination of enzyme activity from the same DBS is
essential. Regarding test sensitivity, the interpretation of
neopterin and biopterin concentration per hemoglobin is
more valid than the interpretation of neopterin and
biopterin per liter. Percentage of biopterin, of the sum of
neopterin and biopterin should always be calculated. In
addition, determination of hemoglobin concentration is
essential as a measure for efficient extraction of neopterin
and biopterin. Although the measurement of neopterin and
biopterin in urine is more sensitive due to the higher
concentrations present, our data prove the usefulness of




DBS Dried blood spot
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Tetrahydrobiopterin (BH4) is the essential cofactor not only
of phenylalanine hydroxylase, but also of nitric oxide
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synthase and of tyrosine and tryptophan hydroxylase, the
two rate-limiting enzymes in the biosynthesis of catechol-
amines and serotonin. Consequently, patients lacking BH4
present with progressive neurological disorders due to
neurotransmitter deficiency in addition to hyperphenylala-
ninemia (HPA) (Blau et al. 2001). Most probably they are
also affected by a depletion of nitric oxide (NO) in the
central nervous system (CNS) (Zorzi et al. 2002). By this
means, an early and specific differential diagnosis in every
newborn with even slightly elevated phenylalanine levels in
newborn screening is essential to enable early substitutive
treatment. Screening for BH4 deficiencies must be done in
all newborns with blood phenylalanine concentrations higher
than 120μmol/l by analysis of neopterin and biopterin in urine
and measurement of DHPR activity in dried blood spots
(DBS). Hereby the four forms of BH4 deficiencies associated
with HPA, i.e., autosomal recessive GTP cyclohydrolase
(GTPCH), 6-pyruvoyl-tetrahydrobiopterin synthase (PTPS),
pterin-4a-carbinolamine dehydratase (PCD) and dihydropter-
idine reductase (DHPR) deficiencies can be diagnosed and
differentiated by specific pterins pattern. The systematic
screening BH4 deficiencies over the last 30 years and the
early initiation of treatment have improved the natural course
of the diseases.
Recently, Zurflüh et al. published a newly developed
method for the measurement of the different pterins
(neopterin, biopterin and pterin) in DBS (Zurflüh et al.
2005). The main advantage of using DBS instead of
urine is the easier sample collection and handling, and
the less expensive shipping of samples at room
temperature instead of on dried ice. In brief, in this
method neopterin and biopterin are eluted from DBS on
filter paper, deproteinized, and measured by reverse-phase
HPLC with fluorometric detection. Neopterin and biopterin
concentrations are calculated according to the amount of
hemoglobin (Hb) in the sample. Pterins pattern in blood
spots was compared with that in urine by linear regression
analysis and a positive correlation for both biopterin +
pterin (pterin is a degradation product of biopterin) and
neopterin has been demonstrated. The authors suggested
that one single DBS card allows the analysis of neopterin
and biopterin, DHPR activity and amino acids, an optimal
alternative for the differential diagnosis of the BH4
deficiencies.
In this study, we evaluated data from a 5-year test period
in our laboratory, in order to validate the usefulness of this
method for the routine differential diagnosis of BH4
deficiencies. For this purpose neopterin and biopterin in
DBS from 362 patients with HPAwere analyzed. Neopterin
and biopterin stability, test sensitivity, and age-dependent




DBS from 362 patients with HPA (age 0.04 – 41.75 years,
mean age 5.2 years) found in newborn screening or during
selective screening due to clinical symptoms were mea-
sured before introduction of diet. Parallel urine samples
were obtained from 338 patients. All tests were performed
within routine clinical and biochemical investigation and in
accordance with local regulations.
Sample preparation and HPLC of pterins
The term ‘pterins’ is used for different metabolites; e.g.,
neopterin, biopterin, and pterin. Pterin itself is a main
degradation product resulting from a side-chain cleavage of
BH4 (Niederwieser et al. 1986) and most probably also of
dihydroneopterin.
Sample preparation was performed as described before
(Zurflüh et al. 2005). Briefly, four DBS (6 mm diameter
each) were cut out of the filter paper. Neopterin and
biopterin were extracted with 0.25 ml of 20 mmol/L HCl
for 30 sec in an ultrasonic bath (Sonorex RK31, Bandelin),
and for 10 min at room temperature. Extracts were
centrifuged at 1’800xg for 5 min. Hemoglobin (Hb) content
was determined in the clear supernatant (HemoCue Pho-
tometer, Ängelholm, Sweden). The remaining supernatant
was ultra-filtrated on Ultrafree (NMWL 10000; Millipore)
at 5000g for 5 min and analyzed by HPLC and fluores-
cence detection without prior oxidation according to (Blau
and Thöny 2008). Separation was achieved on a C8
Spherisorb, 5 μm pre-column 40×4.6 mm) and an ODS-1
Spherisorb, 5 μm analytical column (250×4.6 mm) (both
from Stagroma, Rheinach, Switzerland). A 1.5 mmol/L
potassium hydrogen phosphate buffer, pH 4.6, with 8% (v/v)
methanol was used as a mobile phase. Neopterin and
biopterin were detected by native fluorescence (λex
350 nm; λem 450 nm). Recovery of neopterin and biopterin
from DBS determined by spiking samples with
corresponding standard of neopterin (20 nmol/L), biopterin
(20 nmol/L), and pterin (5 nmol/L) yielded 63-69%.
Neopterin and biopterin concentration was expressed as
nmol/L and as nmol per gram of hemoglobin (nmol/g Hb)
content. Percentage of biopterin (%biopterin) was calculated
according to the formula: %biopterin=100 * biopterin/
(neopterin + biopterin).
Stability to light exposure
DBS from one healthy adult person were kept either at
daylight or in dark at room temperature for up to 14 days.
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Neopterin and biopterin were analyzed immediately after the
blood draw (T0) and after one, five, seven and 14 days.
Statistical analyses
Descriptive statistics and calculation of sensitivity were
done with SPSS 17.0 or MS Excel 2003.
Results
Pterins (neopterin, biopterin and pterin) were measured in
DBS on filter paper from 362 patients with HPA. A parallel
urine sample was obtained in 338 patients. In 64 patients BH4
deficiency was detected. Twenty seven patients were
diagnosed with PTPS deficiency, 7 patients with GTPCH
deficiency and 30 patients with DHPR deficiency. Diagnosis
was confirmed by either urinary or CSF neopterin and
biopterin or in the case of DHPR deficiency by the absence
of enzyme activity in DBS. In the remaining 298 patients
HPA was most probably caused by deficiency of PAH. All
patients have been tabulated in the international database of
BH4 deficiencies BIODEF (http://www.biopku.org). The
median age at diagnosis in PTPS-deficient patients was
2.37 years (range 0.04 – 7.7 yrs.), in GTPCH-deficient
patients 5.1 years (range 0.92 – 9.58 yrs.) and in DHPR-
deficient patients 3.23 years (range 0.07 – 8.4 yrs.).
Age-related reference values
Neopterin and biopterin concentrations in DBS were
expressed either as nmol/L or as nmol per gram of
hemoglobin [nmol/g Hb]. The reason for calculating pterins
concentration in relation to the hemoglobin content is
because of the relative high amount of neopterin and
biopterin in red blood cells (Ponzone et al. 1993).
Reference values of 298 patients with HPA, in whom BH4
deficiency was excluded, show a broad variation. Mean
and 5th – 95th percentile were comparable with results
from the pilot study (Zurflüh et al. 2005), but since
normal values for neopterin and biopterin in urine are age-
dependant (Blau et al. 2005), age dependency was also
investigated in this group. In parallel to the age groups for
pterin excretion in urine, we distinguished two age groups
(<10 years and >10 years). Since pterin is a degradation
product of BH4, a sum of biopterin and pterin were
initially used for the differential diagnosis (Zurflüh et al.
2005). Neopterin and biopterin concentrations in DBS
were found to be higher in children younger than 10 years
(Table 1). Significant (p<0.001) differences were found
for neopterin [nmol/L] as well as for neopterin/g Hb,
biopterin + pterin/g Hb and %biopterin (Table 1). Reference
values for biopterin and biopterin + pterin [nmol/L] and
biopterin/g Hb were not significantly different between
the two age groups. Only one patient from the group of
BH4-deficient patients was older than 10 years. Conse-
quently, age-dependency could not be evaluated for these
patients and for comparison with HPA patients the
reference values for children younger than 10 years were
applied.
Pterins pattern in BH4 deficiencies
Results of the neopterin and biopterin analyses in DBS
from patients with BH4 deficiencies are summarized in
Table 1 and a diagnostic flow-chart following an abnormal
newborn screening for elevated Phe is shown in Fig. 1.
Patients with PTPS deficiency show clearly increased
concentrations of neopterin, nearly no biopterin, and very
low percentage of biopterin. Patients suffering from
GTPCH deficiency are characterized by very low concen-
trations of both biopterin and neopterin. In contrast, most
patients suffering from DHPR deficiency have normal
neopterin and biopterin levels in DBS (Fig. 2).
Table 1 Reference values for neopterin and biopterin [nmol/L or
nmol/g Hb] as well as %biopterin in patients with hyperphenylalani-
nemia (HPA) and 6-pyruvoyl-tetrahydropterin synthase (PTPS)
deficiency, GTP cyclohydrolase I (GTPCH) deficiency, and dihy-
dropteridine reductase (DHPR) deficiency. Reference values for
biopterin [nmol/L] and biopterin per gram hemoglobin were not
significantly different between the two age groups (median, 5 – 95
percentiles, * 25–75 percentile, recovery corrected). Neo = neopterin,
Bio = biopterin, Pte = pterin, Hb = hemoglobin, %Bio = 100*Bio/
(Neo + Bio)
Neo [nmol/L] Bio [nmol/L] Neo [nmol/g Hb] Bio [nmol/g Hb] Bio [%]
HPA (n=271) 5.94 (1.7 – 25.87) 2.75 (0.67 – 8.87) 1.35 (0.35 – 4.62) 0.53 (0.15 – 1.68) 27.71 (11.16 – 61.71)
< 10 years
HPA (n=27) 2.79 (0.91 – 10.13) 2.75 (0.67 – 8.87) 0.39 (0.15 – 1.88) 0.53 (0.15 – 1.68) 51.05 (12.97 – 73.64)
> 10 years
PTPS (n=27) 23.96 (2.22 – 75.37) 0 (0 – 0.44) 4,46 (0.55 – 9.55) 0 (0 – 0.07) 0 (0 – 3.08)
GTPCH (n=7) 0.56 (0 – 1.03)* 0 (0 – 0.7)* 0.13 (0 – 0.15)* 0 (0 – 0.09)* 0 (0 – 40.3)*
DHPR (n=30) 3.78 (1.22 – 33.56) 4.59 (0.40 – 14.08) 0.80 (0.26 – 6.17) 0.81 (0.2 – 4.31) 49.41 (12.67 – 77.56)
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Test sensitivity
Although in most cases a clear diagnosis of a BH4
deficiency is possible by the analysis of neopterin and
biopterin in DBS, the data revealed an overlap between
pathologically decreased values in BH4-deficient patients
and the lower normal range in HPA patients (Fig. 2). This is
critical for a diagnosis of PTPS and GTPCH deficiency. To
clearly define the sensitivity and to improve test interpre-
tation, test sensitivities all neopterin and biopterin results
were analyzed. In addition sensitivity for urinary neopterin
and biopterin analysis for PTPS and GTPCH deficiencies
were calculated as well. Since the diagnosis of BH4
deficiencies always requires a combined interpretation of
neopterin, biopterin, and percentage of biopterin, test
sensitivity for these two pterins was also calculated.
Fig. 1 Diagnostic algorithm following abnormal newborn screening
(NBS) for PKU. Every positive test for PKU needs to be confirmed by
a quantitative analysis of phenylalaine (Phe) and tyrosine (Tyr) in
plasma. Samples normal in the quantitative Phe and Tyr test need no
further testing for hyperphenylalaninemia (HPA) variants. Samples
with both elevated Phe and Tyr need another quantitative testing in
order to confirm/exclude causes of HPA other than PKU or
tetrahydrobiopterin (BH4) deficiency. Patients with confirmed HPA
(high Phe and normal or low Tyr) need to be tested for the cofactor
BH4 deficiency. This should be done before introducing the diet and at
high blood Phe levels. Dried blood spots (DBS) or random urine (U)
can be used for the differential diagnosis and depending on the profile
of neopterin (Neo), biopterin (Bio), and primapterin (Pri) and
dihydropteridine reductase (DHPR) activity in DBS, diagnosis of
following BH4 deficiencies can be established: GTP cyclohydrolase I
(GTPCH) deficiency (low or no detectable neopterin and biopterin), 6-
pyruvoyl-tetrahydropterin synthase (PTPS) deficiency (high neopterin
and low or no detectable biopterin), dihydropteridine reductase
(DHPR) deficiency (normal neopterin and normal or elevated
biopterin and no DHPR activity), and pterins-4a-carbinolamine
dehydratase (PCD) deficiency (elevated neopterin, low-normal
biopterin, and elevated primapterin). n: normal
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Percentage of biopterin is an additional important parameter
for the correct interpretation of results.
Interpretation of the test sensitivity for GTPCH deficiency
was limited due to the low number of cases (n=7).
Nevertheless, test sensitivity for neopterin and biopterin
reaches 100% when expressed per gram Hb, while for
biopterin + pterin/g Hb a sensitivity of 85.7% is achieved.
For neopterin and biopterin alone (expressed as nmol/L)
sensitivity reaches 100% and 71.4%, respectively. The
combined interpretation of biopterin and neopterin (both
nmol/L and nmol/g hemoglobin) results in 100% sensitivity
(Fig. 3a). The same result was found for urine analyses where
test sensitivity both for biopterin and neopterin reaches 100%.
In patients with PTPS deficiency (n=27) a single parameter
analysis of either neopterin or biopterin is less sensitive. Best
results are achieved for biopterin both per liter or gram
hemoglobin (85.5% and 96.3%, respectively). The increase of
neopterin concentration in PTPS patients, compared to
controls, is less sensitive (40.7% and 44.4 %; see Fig. 3b).
The best test sensitivity in PTPS-deficient patients is
achieved by a combined interpretation of neopterin and
biopterin related to hemoglobin content (96.3%, Fig. 3b),
followed by the concentration of neopterin and biopterin per
liter (92.6%, Fig. 3b). Additional evaluation of biopterin +
pterin either per liter or per gram hemoglobin does not
further improve the sensitivity of the test. Urine analysis was
possible in 20 patients with PTPS and showed for neopterin
95% test sensitivity while for the decreased concentration of
biopterin 100% sensitivity is reached. Several PTPS-
deficient presented normal pterin concentrations (data not
shown). Thus, the calculation of biopterin + pterin may
result in too high values and in contrast to the previous
publication (Zurflüh et al. 2005) should be not used.
Stability to light exposure
Stability of neopterin and biopterin to light exposure was





























Fig. 2 Pterin concentrations in
DBS of patients with
hyperphenylalaninemia






(DHPR) deficiency. The upper
part (a) shows the pterins
concentrations in nmol/L, the
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kept during 14 days either at day-light or in dark. This time
frame was chosen to be sufficient to send a DBS by regular
mail to the laboratory. Neopterin and biopterin were
analyzed right after the blood draw (t0) and after one, five,
seven and 14 days.
Neopterin concentration from the DBS kept under light
was decreased by around 6% after one day compared to
DBS kept in the dark. No further difference was observed
during the following 7 days but after 14 days neopterin was
found to be 22% lower in DBS under light exposure.
Comparably, biopterin levels under exposure to light were
around 11% lower after one day. After 14 days biopterin
levels were around 13% lower compared to levels form
DBS kept in dark.
Hemoglobin quantification
Hemoglobin was measured in all 362 DBS. The median
concentration was 8.0 g/dl. 95% of values were higher than
4.0 g/dl (5% percentile) and the minimal concentration was
1.0 g/dl.
Discussion
Blood collection on filter paper (Guthrie cards) currently
plays a major role in the diagnosis of metabolic diseases.
Apart from newborn screening by tandem mass-
spectrometry, filter paper DBS are used for the measure-
ment of a number of metabolites in serum or plasma
including amino acids, acylcarnitines, sterols or for enzy-
matic activities like DHPR (Arai et al. 1982) or lysosomal
enzymes (Duffey et al. 2010; Paglia et al. 2010). The major
advantage in DBS on filter paper is explained by the
practical application of this medium. Samples can be
transported over a long distance at room temperature and
only a minimal sample volume is needed.
In children detected in the newborn screening with HPA
(phenylalanine levels higher than 120 μmol/L), neopterin
and biopterin analysis in urine was used for many years as a
differential diagnosis of classical phenylketonuria (PKU)
and defects in BH4 biosynthesis or recycling (Blau et al.
2010). A recently developed method for the measurement
of neopterin and biopterin in DBS demonstrated a good
Fig. 3 Test sensitivity in seven
patients with GTP
cyclohydrolase I (GTPCH)




(b). ┌─┐ indicates sensitivity of
combined parameter
interpretation. Neo = neopterin;
Bio=biopterin; Pte = pterin;
Bio + Pte = biopterin + pterin;
Hb = hemoglobin;
%Bio = 100*Bio/(Neo + Bio)
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correlation between the pterins pattern in DBS and urine for
70 patients with HPA (Zurflüh et al. 2005). The aim of our
study was to re-evaluate the usefulness of this method in a
large population of patients with HPA over longer period of
time and to establish reference values for both BH4-
deficient and BH4-non-deficient HPA patients. In addition,
we tested the sensitivity for each parameter and assessed
the value of expressing neopterin and biopterin values to
hemoglobin in the DBS sample.
As has been previously shown in urine, concentrations
of neopterin and biopterin in DBS are higher in younger
patients and show with exception of biopterin, biopterin +
pterin and biopterin per hemoglobin significant age-related
differences. For this reason we established reference ranges
for children below and above 10 years of age. In children
younger than 10 years a broad variation of neopterin and
biopterin concentration is observed most probably due to
differences in the corresponding blood phenylalanine
concentration (Ponzone et al. 1993). However, one should
keep in mind that any activation of immune system results
in an elevation of urinary neopterin, but not biopterin (Dale
et al. 2009; Murr et al. 2002). This may result in a relative
low percentage of biopterin in blood or urine.
So far only values for neopterin and biopterin of four
patients with BH4 deficiency investigated by dried blood
spots were published (Zurflüh et al. 2005). In our study 27
patients with PTPS deficiency, seven patients with GTPCH
deficiency and 30 patients with DHPR deficiency were
diagnosed. The pattern of DBS neopterin and biopterin in
patients with BH4 disorders was identical with that found in
urine. Pterins pattern allows a diagnosis and differentiation
of patients with PTPS and GTPCH deficiency. As has been
found with urinary determinations, reliable diagnosis by
neopterin and biopterin analysis alone is not possible in
DHPR deficiency. Here the reduced enzyme activity is
decisive, and thus DHPR activity measurement in DBS is
essential in every child with HPA. Reference ranges for
BH4-deficient patients younger than 10 years were calculated
In order to optimize test interpretation, sensitivity for
results of individual pterins was investigated in PTPS and
GTPCH deficient patients. Best sensitivities were reached
in GTPCH-deficient patients by the marked reduction of
neopterin (at elevated blood Phe concentrations) both per
liter and per hemoglobin content. Interestingly, for the
reduced biopterin concentrations in GTPCH patients test
sensitivity differs between the results per hemoglobin and
per liter. Only biopterin concentrations expressed per
hemoglobin detected all patients.
In PTPS-deficient patients the single parameter analyses
yielded more equivocal results. The decreased concentra-
tion of biopterin proved to be more relevant for the
diagnosis than the increased concentration of neopterin.
However, in contrast to normal controls, PTPS-deficient
patients always have extremely low %biopterin. Also,
neopterin and biopterin calculated per hemoglobin content
are more discriminative than those expressed as nmol/l per
liter. Even with the combined interpretation of neopterin
with biopterin or biopterin + pterin per liter, the sensitivity
remains below the results of biopterin/g Hb alone (92.6% or
81.5% vs. 96.3%). For that reason determination of
hemoglobin concentration in the sample and expression of
neopterin and biopterin results according to hemoglobin
concentration must be part of the test procedure. In our
population 95% of samples had a hemoglobin concentration
of higher than 4 g/dl. Although a DBS with only 1 g/dl
hemoglobin revealed reliable results, we suggest a careful
evaluation of each result with hemoglobin concentrations
below 4 g/dl. Analysis of urinary neopterin and biopterin in
PTPS-deficient patients reached a test sensitivity of 100%.
It is important to note that in our study no patients with
pterin-4a-carbinolamine dehydratase (PCD) deficiency
were detected by pterins analysis from DBS. However, in
the same test period we did not detect any PCD-deficient
patients by urinary pterins either. PCD deficiency is
characterized by the presence of low concentrations of
primapterin in urine. HPA is present only in the early
neonatal period in these patients. PCD deficiency is
considered as a benign disease, although one patient was
reported as having mild neurological signs including tremor
in the neonatal period and with tendency to hyper- or
hypotonia and motor delay (Dhondt 2006).
In summary, our data confirm the usefulness of DBS for
the screening for BH4 deficiency. Although, the measure-
ment of urinary neopterin and biopterin is more sensitive
due to higher concentrations of pterins in urine, the DBS
method is reliable and safe. No false negative tests were
reported in the 5-year period. Phenylalanine, tyrosine,
pterins (neopterin and biopterin) and DHPR activity can
be measured from one single DBS, which facilitates
significantly sample handling and transport costs. It is
important to note that neopterin and biopterin in body fluids
are sensitive to temperature, oxygen, and light (Zurflüh
et al. 2005). We showed that both neopterin and biopterin
levels show a tendency to be lower under light exposure,
but this difference is not statistically significant and has no
impact on the differential diagnosis. Nevertheless, exposure of
DBS samples to sunlight should be avoided. In conclusion,
this method, although not superior in analytical performance,
is a practical, less expensive, and safe substitute for analysis of
neopterin and biopterin in urine and a useful tool for the
differential diagnosis of BH4 deficiencies.
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